

Annex F: Integration of Board decisions (Dec 2024) into ELTRACO policies

Decision 9: ELTRACO, including Catalytic Phase

Decision	Eligibility Policy	Co-Financing Policy	Comments
Shift A			
<p>Under Shift A, approved:</p> <p>i. Directly linking country co-financing contribution to the price of the vaccines for specific vaccine markets for Initial Self-Financing Countries, where certain conditions are met (as outlined in Annex B to Doc 06bii);</p>	n/a	<p>4. Procedures and Funding Levels for Routine Vaccines</p> <p>4.2 Initial self-financing</p> <p>4.2.1 Countries in the initial self-financing phase are required to contribute US\$ 0.20 per dose, with no annual increase. For specific vaccines that meet specific conditions and are approved by the Board, a price fraction applies. Further details on specific conditions at vaccine level can be found in the Gavi's operational guidelines.</p>	To be reflected in the Gavi Funding Guidelines.
<p>Under Shift A, approved:</p> <p>ii. Determining the percentage of the vaccine price that the country will pay</p>	n/a	n/a	For reference when determining specific price fractions for vaccine programmes

in co-financing according to the principles of: minimal disruption to current co-financing obligations, uniform payment for the same product across Initial Self Financing (ISF) countries, and affordability of new vaccines;			in ISF countries.
Under Shift A, approved: iii. Human Papillomavirus (HPV) and pneumococcal vaccine (PCV) as the first vaccine markets to meet the specific conditions under decision point a)(i), and hence the first markets for application of Shift A, with co-financing set at 4% for HPV and 7% for PCV of the vaccine price ¹ , in accordance with the principles of decision point a)(ii); and ¹	n/a	n/a	To be reflected in the Gavi Funding Guidelines. Please note: Gavi Board decisions to determine or modify co-financing requirements for specific vaccine programmes or countries supersede the co-financing policy.

Calculated based on current equivalence to US\$ 0.20 per dose for the highest cost product selected by countries for each vaccine			
<p>Under Shift A, approved:</p> <p>iv. Following the application of Shift A to HPV and PCV as per decision point a) (iii), that future applications of Shift A to other vaccine markets, as well as the appropriate co-financing, will be reviewed and applied by the Secretariat and approved by the Board, in accordance with the considerations and principles specified in Annex B to Doc 06bii and in decision point a)(ii), leveraging market shaping roadmap review cycles and in</p>	n/a	n/a	For reference when determining specific price fractions for vaccine programmes in ISF countries.

consultation with Alliance market shaping partners.			
Shift B			
<p>Under Shift B, approved:</p> <p>i. Increasing the Gavi eligibility threshold to US\$ 2,300 Gross National Income (GNI) per capita (p.c.) in 2026; and</p>	<p>4. Procedures and Thresholds</p> <p>4.2 Gavi-eligible countries: GNI p.c. is used to determine eligibility for Gavi support on an annual basis. The threshold for eligibility for Gavi support is US\$ 2,300 GNI p.c. in 2026. The threshold for eligibility is updated annually using the inflation adjustments the World Bank makes annually to its income categories.</p>	n/a	-
<p>Under Shift B, approved:</p> <p>ii. Providing countries that regain eligibility with a downward adjustment in co-financing for individual Gavi-supported</p>	n/a	<p>4.6 Countries moving to earlier phases of eligibility</p> <p>4.6.1 If a country in the preparatory transition phase moves back to the initial self-financing phase, it is expected to continue</p>	Reference to countries moving back to ISF phase has been added to cover the exceptional case where a country would regain eligibility

vaccine programmes, including self-financed ones, to 80% at the point at which they re-enter Preparatory Transition (PT) phase.		contributing to the co-financing of vaccines at the same price fraction as in its last year in the preparatory transition phase, with no annual increase in the price fraction. 4.6.2 If a country regains Gavi eligibility into either the initial self-financing or preparatory transition phase and has introduced Gavi-supported vaccine programs that have become fully self-financed or have a price fraction above 80%, it will have the price fraction for each of these programs reduced to 80%.	directly into the ISF phase.
SIDS package			
Under the Small Island Developing States (SIDS) Package, i. Approved increasing Accelerated Transition (AT) phase for SIDS to 12 years (...)	2. Definitions 2.4 Small Island Developing States (SIDS): A distinct group of States and Associate Members of United Nations regional commissions that face	n/a	-

	<p>unique social, economic and environmental vulnerabilities as defined by the United Nations.</p> <p>4. Procedures and Thresholds</p> <p>4.3 Initial self-financing, preparatory transition and accelerated transition phases:</p> <p>4.3.3 A Gavi-eligible country enters the accelerated transition phase when its three-year average GNI p.c. as well as its most recent GNI p.c. are above the Gavi eligibility threshold (see 4.2) and the country has a co-financing share (as defined in the co-financing policy) of at least 35% of vaccine costs .The accelerated transition phase lasts eight years,</p>		
--	---	--	--

	except for Small Island Developing States in this phase where it extends to twelve years.		
Under the Small Island Developing States (SIDS) Package, i. Approved (...) and providing a one-time downward adjustment in co-financing for individual Gavi-supported vaccine programmes, including fully self-financed ones, to 80% in 2026; and	n/a	n/a	To be reflected in the Multi Year Approvals and Decision Letters indicating country co-financing obligations as of 2026.
Under the Small Island Developing States (SIDS) Package, ii. Noted that SIDS will continue to receive programmatic support, including for campaigns, for the entirety of the AT phase.	n/a	n/a	To be reflected in the allocation of the Health System Strengthening support.
Shift C			
Under Shift C, approved:	n/a	4. Procedures and Funding	-

<p>i. Introducing a co-financing cap for individual Gavi-supported vaccine programmes for countries in Preparatory Transition (PT) of 80%;</p>		<p>Levels for Routine Vaccines 4.3 Preparatory transition 4.3.3 Thereafter, the price fraction, which is applied equally across all vaccines, increases by 15% each year up to a maximum of 80% until the country enters the accelerated transition phase.</p>	
<p>Under Shift C, approved:</p> <p>ii. Providing a downward adjustment in co-financing to individual Gavi-supported vaccine programmes, including fully self-financed ones, to 80% for countries in PT above the co-financing cap; and</p>	n/a	n/a	<p>To be reflected in the Multi Year Approvals and Decision Letters indicating country co-financing obligations</p>
<p>Under Shift C, approved:</p> <p>iii. For countries in PT, establishing an introductory co-financing cap of 35% for all new vaccines, with the exception</p>	n/a	<p>4. Procedures and Funding Levels for Routine Vaccines 4.3 Preparatory transition 4.3.4 For any new vaccine introduction, the same price</p>	<p>Exemption of measles and measles-rubella to be reflected in the Gavi Funding Guidelines. Please note: Gavi Board decisions to</p>

of measles and measles-rubella (MR), which will remain as per the current Board decisions.		fraction as that applied to other vaccines in the portfolio for that year will be used, with a maximum limit of 35%.	determine or modify co-financing requirements for specific vaccine programmes or countries supersede the co-financing policy.
Shift D			
Under Shift D, approved: i. For countries in AT, establishing an introductory co-financing cap of 35% for all vaccines, with the exception of Measles and MR which will remain as per the current Board decisions; and	n/a	4. Procedures and Funding Levels for Routine Vaccines 4.4 Accelerated transition 4.4.4 For any new vaccine introduction, the same price fraction as that applied to other vaccines in the portfolio for that year will be used, with a maximum limit of 35% (...)	Exemption of measles and measles-rubella to be reflected in the Gavi Funding Guidelines. Please note: Gavi Board decisions to determine or modify co-financing requirements for specific vaccine programmes or countries supersede the co-financing policy.
Under Shift D, approved: ii. Providing AT countries with eight years of vaccine support for all new vaccines introduced	n/a	4. Procedures and Funding Levels for Routine Vaccines 4.4 Accelerated transition 4.4.4 (...) Countries will receive eight	-

during AT, regardless of when during the AT phase they are introduced.		years of vaccine procurement support from the year of introduction, regardless of whether transition occurs during the eight years, following the same price fraction increase described in 4.4.3. Such Gavi support during any years after AT only applies to products procured at the same prices as applicable to Gavi-eligible countries during these years, otherwise Gavi support is limited to the duration of AT.	
Shift E			
Under Shift E, approved: i. Using multiple indicators measuring immunisation coverage to assess programmatic performance of AT countries, aligning directly with the indicators and levels used in the Health Systems	4. Procedures and Thresholds 4.3 Initial self-financing, preparatory transition and accelerated transition phases: 4.3.5 A country in accelerated transition phase, at risk of unsuccessful programmatic transition may	n/a	To be reflected in the Gavi Funding Guidelines.

allocation model in Gavi 6.0;	apply for five years of additional targeted HSIS support following their transition out of the accelerated transition phase. This support aims to address acute programmatic challenges countries may experience to aid their successful transition out of Gavi support. Further details on this support can be found in the HSIS policy and Gavi's operational guidelines.		
Under Shift E, approved: ii. Providing five years of additional programmatic support to reinforce programmatic capacities for countries post-AT who meet the specified criteria; and		n/a	
Under Shift E, approved: ii. Removing the 90% coverage threshold limit for three doses of pentavalent vaccine (Penta3) for approval of new Health System Strengthening grants for countries in AT.	4.8 Subject to availability of funding and approval in accordance with Gavi's processes, Gavi will honour all existing multi-year commitments for Health Systems Strengthening (HSS) support to countries in accelerated transition for	n/a	Paragraph 4.8 from the previous policy version is not included in the new version.

	Gavi-eligible countries. Approval of new HSS grants for countries in accelerated transition are restricted to those countries with Penta3 coverage below 90%. (removed from policy)		
Shift F			
<p>Under Shift F, approved:</p> <p>i. Allowing Gavi to provide, for countries that experience widespread, large-scale conflict or disaster of such magnitude that profoundly hampers the proper functioning of government, either (i) co-financing waivers of up to three years at any one time, or (ii) partial co-financing obligations, as per the country context.</p>	n/a	<p>7. Exceptions</p> <p>7.1 A country may be exempted from the co-financing rules described above in only three rare and exceptional circumstances:</p> <p>7.1.1 In the case where a country experiences widespread, large-scale conflict or disaster of such magnitude that profoundly hampers the proper functioning of government (humanitarian crisis), it may be considered for a co-financing waiver of up to three years or, alternatively, a</p>	-

		partial co-financing obligation.	
Under Shift F, approved: ii. That co-financing obligations do not apply where Gavi channels vaccines and support directly through Alliance and other partners in exceptional emergency situations and humanitarian settings.	n/a	7. Exceptions 7.1 A country may be exempted from the co-financing rules described above in only three rare and exceptional circumstances: (...) 7.1.3 Co-financing obligations do not apply where Gavi channels vaccines and support directly through Alliance and other partners in exceptional emergency situations and humanitarian settings.	-
Catalytic Phase			
Under the Catalytic Phase ² , approved: i. The overall scope and eligibility for the Catalytic Phase, including vaccines in scope, as outlined in Annex C to Doc 06bii;	4. Procedures and Thresholds 4.4 Catalytic Phase: 4.4.1 A country is in the catalytic phase if it is not Gavi-eligible and a) its GNI p.c. is equal to or below the World Bank's lower-middle income	1. Purpose & Objective 1.2 This policy covers: a) vaccine co-financing levels for Gavi-eligible countries as defined in the eligibility and transition policy. There is no country co-financing for vaccines introduced in	-

<p>² <i>Eligible countries are former- and never-Gavi eligible countries classified by the World Bank as lower middle-income countries (LMICs) or eligible to borrow from the International Development Association (IDA)</i></p>	<p>threshold, or b) if they are eligible to borrow from the International Development Association (IDA-eligible). Countries that have transitioned out of the accelerated transition phase and meet one of these criteria are referred to as former Gavi-eligible. Countries that have never been Gavi-eligible and meet one of these criteria are also part of the catalytic phase.</p> <p>4.4.2 Countries can enter the catalytic phase at any point during Gavi strategic period and they remain in this phase for its entirety. A country whose GNI p.c. rises above the World Bank's lower middle-income</p>	<p>catalytic phase. Vaccine support for countries in the catalytic phase is outlined in the Framework for Gavi Funding to Countries, and funding framework and vaccine programme guidelines</p>	
--	---	---	--

	threshold or is no longer IDA-eligible will not be in the catalytic phase in the next strategic period.		
Under the Catalytic Phase, approved: ii. Support may be channelled towards vaccine optimisation activities, including switches, to support lower middle-income countries achieve financial sustainability of their vaccine programmes. This would include support for technical assistance and one-off costs, not vaccine doses;	n/a	n/a	For reference when determining specific support for countries in the Catalytic Phase.
Under the Catalytic Phase, approved: iii. Applying the proposed performance indicators and prioritisation criteria	n/a	n/a	For reference when determining specific support for countries in the Catalytic Phase.

(outlined in this paper) in determining eligibility for Targeted Intervention support to Former-Gavi-eligible countries experiencing backsliding; and			
Under the Catalytic Phase, approved: iv. Maintaining the in-principle eligibility of both Former- and Never-Gavi eligible countries for potential Fragility Support (per June 2022 Board Decision 13).	n/a	n/a	For reference when determining specific support for countries in the Catalytic Phase.
Other decisions			
i Approved that the new co-financing rules outlined in the above decision points can be used to inform the approval processes starting in early 2025 for implementation from 2026.	n/a	n/a	To be reflected in the Multi Year Approvals and Decision Letters indicating country co-financing obligations

<p>Approved the application of decision points (d)(iii), (e)(i) and (e)(ii) in 2025 in situations where countries are ready to introduce vaccines, to avoid delaying such introductions, with an additional estimated financial implication of US\$ 9.5 million (US\$ 0.5 million in 2025 and US\$ 9 million in Gavi 6.0);</p>	n/a	n/a	To be reflected in the Multi Year Approvals and Decision Letters indicating country co-financing obligations
<p>Approved that for currently eligible Gavi countries expected to benefit from decision points (b)(ii) and (c)(i) in 2026, the co-financing shared are held constant at 2024 levels in 2025 for any individual Gavi-supported vaccine programme with a co-financing share at or above 80%, at an</p>	n/a	n/a	To be reflected in the Multi Year Approvals and Decision Letters indicating country co-financing obligations

additional estimated cost of US\$ 3.9 million in 2025; and			
Requested that the Secretariat put forward options for addressing the pace of change in co-financing for PT countries. This will be part of a series of other potential investments to be explored by the Board in 2025 as part of further prioritisation of programmes when future resources and other Gavi cost areas are more clear.	n/a	n/a	To be reflected in the Gavi 6.0 recalibrations exercises.